Financial reports
10-Q
2021 Q3
Quarterly report
10 Nov 21
10-Q
2021 Q2
Quarterly report
9 Aug 21
10-Q
2021 Q1
Quarterly report
10 May 21
10-K
2020 FY
Annual report
23 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K
2019 FY
Annual report
25 Feb 20
10-Q
2019 Q3
Quarterly report
7 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
Current reports
8-K
Completion of Acquisition or Disposition of Assets
24 Nov 21
8-K
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
12 Oct 21
8-K
Adamas reports second quarter 2021 financial results
9 Aug 21
8-K
Departure of Directors or Certain Officers
11 Jun 21
8-K
Submission of Matters to a Vote of Security Holders
4 Jun 21
8-K
Adamas reports first quarter 2021 financial results
10 May 21
8-K
Other Events
25 Feb 21
8-K
Adamas Reports Fourth Quarter and Full Year 2020 Financial Results
23 Feb 21
8-K
Entry into a Material Definitive Agreement
1 Feb 21
8-K
Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021
13 Jan 21
Registration and prospectus
15-12B
Securities registration termination
6 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
S-8 POS
Registration of securities for employees (post-effective amendment)
24 Nov 21
Proxies
DEFA14A
Additional proxy soliciting materials
19 Apr 21
DEF 14A
Definitive proxy
19 Apr 21
DEFA14A
Additional proxy soliciting materials
23 Apr 20
DEF 14A
Definitive proxy
23 Apr 20
DEFA14A
Additional proxy soliciting materials
25 Apr 19
DEF 14A
Definitive proxy
25 Apr 19
DEFA14A
Additional proxy soliciting materials
26 Apr 18
DEF 14A
Definitive proxy
26 Apr 18
DEF 14A
Definitive proxy
18 Apr 17
DEFA14A
Additional proxy soliciting materials
18 Apr 17
Other
EFFECT
Notice of effectiveness
2 Dec 21
EFFECT
Notice of effectiveness
3 Dec 19
CORRESP
Correspondence with SEC
25 Nov 19
CORRESP
Correspondence with SEC
21 Nov 19
UPLOAD
Letter from SEC
20 Nov 19
UPLOAD
Letter from SEC
15 Oct 19
CORRESP
Correspondence with SEC
7 Oct 19
SEC STAFF
SEC staff action: Order
26 Sep 19
UPLOAD
Letter from SEC
19 Sep 19
SEC STAFF
SEC staff action: Order
11 Sep 19
Ownership
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 22
SC 13G/A
Stonepine Capital Management, LLC
14 Feb 22
SC 13G/A
Opaleye Management Inc.
26 Jan 22
SC 13G/A
FMR LLC
10 Dec 21
4
MICHAEL BIGHAM
24 Nov 21
4
DAVID L MAHONEY
24 Nov 21
4
Neil F. McFarlane
24 Nov 21
4
Christopher B Prentiss
24 Nov 21
4
William W. Ericson
24 Nov 21
4
Vijay Shreedhar
24 Nov 21